Claro Advisors’s SELLAS Life Sciences SLS Stock Holding History

Claro Advisors’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1	Closed	–	–	801
2018 Q4	$0	Buy	+1	New	+$77	﹤0.01%	1123

Other funds holding SLS

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Claro Advisors's SLS Position: Q1 2019 in Review

Claro Advisors sold out of SELLAS Life Sciences (SLS) in Q1 2019, closing a stake of 1 share.

Claro Advisors first reported a position in SLS in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 11 funds tracked by Wall St. Rank hold SLS as of Q1 2019.

Claro Advisors reported no remaining SELLAS Life Sciences position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 1 SELLAS Life Sciences share in Q1 2019.
Claro Advisors first reported a position in SELLAS Life Sciences in Q4 2018 and held it in 1 quarter.
Claro Advisors's SELLAS Life Sciences position peaked at $0 in Q4 2018.
11 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.